Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with
relapsed or refractory diffuse large B-cell lymphoma. Akt inhibitor MK2206 may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.